Protagonist Therapeutics (PTGX) Debt to Equity (2018 - 2023)

Protagonist Therapeutics has disclosed Debt to Equity across 6 years of filings, most recently posting $0.0 for Q2 2023.

• Debt to Equity for Q2 2023 came in at $0.0, down 88.61% year-over-year; the trailing twelve-month figure through Jun 2023 was $0.0 (down 88.61% YoY), and the FY2022 annual result was $0.0, down 89.32% from the prior year.
• Debt to Equity came in at $0.0 for Q2 2023 at Protagonist Therapeutics, down from $0.0 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.03 in Q2 2021 to a low of $0.0 in Q2 2023.
• The 5-year median for Debt to Equity is $0.01 (2019), against an average of $0.01.
• Across the five-year window, Debt to Equity jumped 432.37% in 2021 and plunged 99.06% in 2022, its largest moves.
• Protagonist Therapeutics' Debt to Equity stood at $0.02 in 2019, then slumped by 38.09% to $0.01 in 2020, then slumped by 69.33% to $0.0 in 2021, then plunged by 89.32% to $0.0 in 2022, then tumbled by 89.37% to $0.0 in 2023.
• The last three Debt to Equity figures came in at $0.0 (Q2 2023), $0.0 (Q1 2023), and $0.0 (Q4 2022), per Business Quant data.